Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]最新文献

Ovarian Cancer Tumour Biology: Genesis 卵巢癌肿瘤生物学:起源

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-09-03 DOI: 10.5772/intechopen.98289

Ján Varga

引用次数: 0

The Role of Ultra-Radical Surgery in the Management of Advanced Ovarian Cancer: State or Art 超根治性手术在晚期卵巢癌治疗中的作用:现状或技术

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-08-12 DOI: 10.5772/intechopen.97638

F. Buruiana, L. Ismail, F. Ferrari, H. S. Majd

引用次数: 1

Targeting Leader Cells in Ovarian Cancer as an Effective Therapeutic Option 靶向领导细胞作为卵巢癌的有效治疗选择

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-06-26 DOI: 10.5772/intechopen.98689

Nazanin Karimnia, G. Ho, A. Stephens, Maree Bilandzic

引用次数: 1

Genetics and Mutational Landscape of Ovarian Sex Cord-Stromal Tumors 卵巢性索间质肿瘤的遗传学和突变景观

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-05-22 DOI: 10.5772/INTECHOPEN.97540

Tran Nguyen, Trang M Tran, Yee Shen Choo, M. Alexiadis, P. Fuller, S. Chu

{"title":"Genetics and Mutational Landscape of Ovarian Sex Cord-Stromal Tumors","authors":"Tran Nguyen, Trang M Tran, Yee Shen Choo, M. Alexiadis, P. Fuller, S. Chu","doi":"10.5772/INTECHOPEN.97540","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.97540","url":null,"abstract":"Ovarian sex cord-stromal tumors (SCST) are uncommon tumors accounting for approximately 8% of all ovarian malignancies. By far, the most common are granulosa cell tumors (GCT) which represent approximately 90% of SCST. SCST are also found in the hereditary syndromes: Peutz-Jeghers syndrome, Ollier disease and Maffucci syndrome, and DICER1 syndrome. Key genomic and genetic events contributing to their pathogenesis have been the focus of recent studies. Most of the genomic studies have been limited to GCT which have identified a number of recurring chromosomal abnormalities (monosomy and trisomy), although their contribution to pathogenesis remains unclear. Recurrent DICER1 mutations are reported in non-hereditary cases of Sertoli cell and Sertoli–Leydig cell tumors (SLCT), while recurrent somatic mutations in both the juvenile (jGCT) and adult forms of GCT (aGCT) have also been reported. Approximately 30% of jGCT contain a somatic mutation in the gsp oncogene, while a further 60% have activating mutations or duplications in the AKT gene. For aGCT, a well characterized mutation in the FOXL2 transcription factor (FOXL2 C134W) is found in the majority of tumors (primary and recurrent), arguably defining the disease. A further mutation in the human telomerase promoter appears to be an important driver for recurrent disease in aGCT. However, despite several studies involving next generation sequencing, the molecular events that determine the stage, behavior and prognosis of aGCT still remain to be determined. Further, there is a need for these studies to be expanded to other SCST in order to identify potential targets for personalized medicine.","PeriodicalId":412940,"journal":{"name":"Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116383681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Cytoreductive Procedures and HIPEC in the Treatment of Advanced Ovarian Cancer 晚期卵巢癌的细胞减少术和HIPEC治疗

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-04-06 DOI: 10.5772/INTECHOPEN.96405

B. Moldovan, Silviu-Tiberiu Makkai-Popa ovan, C. Rad, R. Pisica, Vlad Untaru, D. Stoica

引用次数: 1

Ovarian Cancer: Molecular Classification and Targeted Therapy 卵巢癌:分子分类和靶向治疗

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-02-05 DOI: 10.5772/INTECHOPEN.95967

Febina Ravindran, B. Choudhary

{"title":"Ovarian Cancer: Molecular Classification and Targeted Therapy","authors":"Febina Ravindran, B. Choudhary","doi":"10.5772/INTECHOPEN.95967","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.95967","url":null,"abstract":"Ovarian cancer is the deadliest gynecological cancer among women with an overall 5-year survival rate below 50% due to its asymptomatic nature, diagnosis at advanced stages, and a high recurrence rate after standard therapy in 70% of cases. Ovarian cancers are heterogenous cancers where each subtype possesses a varied morphology and biologic behavior. Accumulating evidence has identified each of these subtypes characterized with specific pathways activated in each along with specific gene alterations. For example, high-grade serous ovarian cancer is characterized by universal TP53 mutation, mucinous ovarian cancer with KRAS mutation and clear cell or endometrioid ovarian cancers with ARID1A mutations. With the current focus of molecular-targeted therapies for cancer, such druggable markers serve as excellent targets for precision therapy and combination therapy. This chapter, provides an overview of the critical molecular pathways activated in the ovarian cancer subtypes with its druggable targets studied in ovarian cancer. We also highlight the implications of miRNAs in chemoresistance and sensitivity in the regulation of ovarian cancer.","PeriodicalId":412940,"journal":{"name":"Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122566986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer 抗寄生虫药物伊维菌素对卵巢癌的抗癌作用

Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title] Pub Date : 2021-01-13 DOI: 10.5772/INTECHOPEN.95556

X. Zhan, Na Li

{"title":"The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer","authors":"X. Zhan, Na Li","doi":"10.5772/INTECHOPEN.95556","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.95556","url":null,"abstract":"Ivermectin is an old, common, and classic anti-parasite drug, which has been found to have a broad-spectrum anti-cancer effect on multiple human cancers. This chapter will focus on the anti-cancer effects of ivermectin on ovarian cancer. First, ivermectin was found to suppress cell proliferation and growth, block cell cycle progression, and promote cell apoptosis in ovarian cancer. Second, drug pathway network, qRT-PCR, and immunoaffinity blot analyses found that ivermectin acts through molecular networks to target the key molecules in energy metabolism pathways, including PFKP in glycolysis, IDH2 and IDH3B in Kreb’s cycle, ND2, ND5, CYTB, and UQCRH in oxidative phosphorylation, and MCT1 and MCT4 in lactate shuttle, to inhibit ovarian cancer growth. Third, the integrative analysis of TCGA transcriptomics and mitochondrial proteomics in ovarian cancer revealed that 16 survival-related lncRNAs were mediated by ivermectin, SILAC quantitative proteomics analysis revealed that ivermectin extensively inhibited the expressions of RNA-binding protein EIF4A3 and 116 EIF4A3-interacted genes including those key molecules in energy metabolism pathways, and also those lncRNAs regulated EIF4A3-mRNA axes. Thus, ivermectin mediated lncRNA-EIF4A3-mRNA axes in ovarian cancer to exert its anticancer capability. Further, lasso regression identified the prognostic model of ivermectin-related three-lncRNA signature (ZNRF3-AS1, SOS1-IT1, and LINC00565), which is significantly associated with overall survival and clinicopathologic characteristics in ovarian cancer patients. These ivermectin-related molecular pattern alterations benefit for prognostic assessment and personalized drug therapy toward 3P medicine practice in ovarian cancer.","PeriodicalId":412940,"journal":{"name":"Ovarian Cancer - Updates in Tumour Biology and Therapeutics [Working Title]","volume":"193 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120848424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1